{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:49:29Z","timestamp":1792234169987,"version":"4.4.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Polycythemia Vera (PV) is a chronic,\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    -negative, myeloproliferative neoplasm characterized by increased hematocrit and platelet\/leukocyte counts, as well as by a high risk of thrombosis and progression to myelofibrosis and acute leukemia. The initial discovery of the\n                    <jats:italic>JAK2<\/jats:italic>\n                    <jats:sup>V617F<\/jats:sup>\n                    driver mutation, followed by a more in-depth knowledge of the mechanisms that regulate inflammation and iron homeostasis, significantly advanced our understanding of PV pathophysiology, paving the way for a shift from symptom-focused vs. biology-focused treatments. PV management is complex and should be individualized, considering age, comorbidities, clinical presentation, disease course, and patient preferences. As such, optimal care requires a dynamic approach involving coordinated collaboration among healthcare professionals, in order to reduce complications, and enhance patients\u2019 quality of life and outcomes. This narrative review explores principles and benefits of integrated care for PV patients, illustrated through two representative clinical cases. We propose that a transdisciplinary approach be adopted throughout the diagnostic and therapeutic continuum for PV to optimize patient outcomes. The review also proposes a novel cytoreductive treatment algorithm in PV going beyond the conventional risk stratification based on patient\u2019s age and history of thrombosis but rather focusing on patient\u2019s characteristics and treatment needs. Finally, we examine ongoing clinical studies and the latest results and insights on PV therapies (including the JAK inhibitor ruxolitinib, the next-generation mono-pegylated type I interferon ropeginterferon alfa-2b, the iron metabolism modifiers and other experimental approaches) that could reshape the standard of care in PV.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06970-w","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:48:47Z","timestamp":1776484127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modern and multidisciplinary care in polycythemia vera"],"prefix":"10.1007","volume":"105","author":[{"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Addimanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Benni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Lo Dato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sabattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dedola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Branzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria B.","family":"Rondinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Reta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benilde","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"La Placa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"11","key":"6970_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"1","key":"6970_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/hematology.2024000576","volume":"2024","author":"A Chee","year":"2024","unstructured":"Chee A, Mead AJ (2024) Molecular profiling in MPN: who should have it and why? Hematol Am Soc Hematol Educ Program 2024(1):524\u2013534","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"6970_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"key":"6970_CR4","first-page":"79","volume":"17","author":"B Beatriz","year":"2025","unstructured":"Beatriz B, Michael D, Ciprian T, Martin G, Monia M, Tomasz S et al (2025) JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications. memo - Magazine Eur Med Oncol 17:79\u201393","journal-title":"memo - Magazine Eur Med Oncol"},{"issue":"4","key":"6970_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/joim.13019","volume":"287","author":"M Hultcrantz","year":"2020","unstructured":"Hultcrantz M, Ravn Landtblom A, Andr\u00e9asson B, Samuelsson J, Dickman PW, Kristinsson SY et al (2020) Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden. J Intern Med 287(4):448\u2013454","journal-title":"J Intern Med"},{"issue":"11","key":"6970_CR6","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J 5(11):e366","journal-title":"Blood Cancer J"},{"issue":"12","key":"6970_CR7","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","volume":"35","author":"A Tefferi","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2021) Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 35(12):3339\u20133351","journal-title":"Leukemia"},{"issue":"9","key":"6970_CR8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T (2023) Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 98(9):1465\u20131487","journal-title":"Am J Hematol"},{"issue":"5","key":"6970_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","volume":"98","author":"M Griesshammer","year":"2019","unstructured":"Griesshammer M, Kiladjian JJ, Besses C (2019) Thromboembolic events in polycythemia vera. Ann Hematol 98(5):1071\u20131082","journal-title":"Ann Hematol"},{"issue":"19","key":"6970_CR10","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124(19):3021\u20133023","journal-title":"Blood"},{"key":"6970_CR11","doi-asserted-by":"crossref","unstructured":"Palandri F, Breccia M, Elli EM, Latagliata R, Benevolo G, Morsia E et al (2025) Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea. Leukemia 39(8):1928\u20131936","DOI":"10.1038\/s41375-025-02646-y"},{"key":"6970_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-023-00835-5","volume":"13","author":"A Duminuco","year":"2023","unstructured":"Duminuco A, Harrington P, Harrison C, Curto-Garcia N (2023) Polycythemia Vera: Barriers to and Strategies for Optimal Management. Blood Lymphat Cancer 13:77\u201390","journal-title":"Blood Lymphat Cancer"},{"issue":"8","key":"6970_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.clml.2024.04.003","volume":"24","author":"AT Kuykendall","year":"2024","unstructured":"Kuykendall AT, Fine JT, Kremyanskaya M (2024) Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians. Clin Lymphoma Myeloma Leuk 24(8):512\u2013522","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"6970_CR14","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3109\/10428194.2013.766732","volume":"54","author":"J Abelsson","year":"2013","unstructured":"Abelsson J, Andr\u00e9asson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B et al (2013) Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma 54(10):2226\u20132230","journal-title":"Leuk Lymphoma"},{"key":"6970_CR15","unstructured":"Caocci G, Palandri F, Guglielmelli P, Patriarca A, Tieghi A, Iurlo A et al (2025) Health-related quality of life in Italian patients with philadelphia-negative myeloproliferative neoplasms compared to the general population: gimema prophecy study. HemaSphere 3837\u20133838"},{"issue":"9","key":"6970_CR16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881","journal-title":"Leukemia"},{"issue":"1","key":"6970_CR17","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.24583","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H et al (2017) The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol 92(1):E5\u2013E6","journal-title":"Am J Hematol"},{"issue":"12","key":"6970_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","volume":"7","author":"S Cerquozzi","year":"2017","unstructured":"Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP et al (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 7(12):662","journal-title":"Blood Cancer J"},{"key":"6970_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/VHRM.S429995","volume":"19","author":"G Benevolo","year":"2023","unstructured":"Benevolo G, Marchetti M, Melchio R, Beggiato E, Sartori C, Biol\u00e9 CA et al (2023) Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera. Vasc Health Risk Manag 19:765\u2013778","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"6970_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114\u2013124","journal-title":"N Engl J Med"},{"key":"6970_CR21","doi-asserted-by":"publisher","first-page":"794240","DOI":"10.1155\/2011\/794240","volume":"2011","author":"R Marchioli","year":"2011","unstructured":"Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T (2011) The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis 2011:794240","journal-title":"Thrombosis"},{"issue":"1","key":"6970_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22\u201333","journal-title":"N Engl J Med"},{"issue":"4","key":"6970_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","volume":"126","author":"T Barbui","year":"2015","unstructured":"Barbui T, Masciulli A, Marfisi MR, Tognoni G, Finazzi G, Rambaldi A et al (2015) White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 126(4):560\u2013561","journal-title":"Blood"},{"issue":"3","key":"6970_CR24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1080\/10428194.2022.2156794","volume":"64","author":"A Coltoff","year":"2023","unstructured":"Coltoff A (2023) Leukocytosis and MPNs: Where do we stand? Leuk Lymphoma 64(3):564\u2013572","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"6970_CR25","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood.2023020232","volume":"143","author":"AT Gerds","year":"2024","unstructured":"Gerds AT, Mesa R, Burke JM, Grunwald MR, Stein BL, Squier P et al (2024) Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood 143(16):1646\u20131655","journal-title":"Blood"},{"key":"6970_CR26","doi-asserted-by":"publisher","first-page":"7753857","DOI":"10.1155\/2021\/7753857","volume":"2021","author":"S Kapor","year":"2021","unstructured":"Kapor S, \u010coki\u0107 V, Santibanez JF (2021) Mechanisms of Hydroxyurea-Induced Cellular Senescence: An Oxidative Stress Connection? Oxid Med Cell Longev 2021:7753857","journal-title":"Oxid Med Cell Longev"},{"issue":"19","key":"6970_CR27","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A et al (2022) A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 139(19):2931\u20132941","journal-title":"Blood"},{"issue":"6","key":"6970_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larr\u00e1n","year":"2012","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hern\u00e1ndez-Boluda JC, Ferrer-Mar\u00edn F et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinic hematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363\u20131369","journal-title":"Blood"},{"issue":"5","key":"6970_CR29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Kerguelen A, Hern\u00e1ndez-Boluda JC, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F, B\u00e1rez A et al (2016) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172(5):786\u2013793","journal-title":"Br J Haematol"},{"issue":"6","key":"6970_CR30","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H et al (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148(6):961\u2013963","journal-title":"Br J Haematol"},{"issue":"11","key":"6970_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.24851","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A et al (2017) A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol 92(11):1131\u20131136","journal-title":"Am J Hematol"},{"issue":"11","key":"6970_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","volume":"8","author":"V De Stefano","year":"2018","unstructured":"De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G et al (2018) Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J 8(11):112","journal-title":"Blood Cancer J"},{"key":"6970_CR33","doi-asserted-by":"crossref","unstructured":"Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G et al (2023) Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. Cancers (Basel) 15(14):3706","DOI":"10.3390\/cancers15143706"},{"issue":"Supplement 1","key":"6970_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2025-1026","volume":"146","author":"D Tremblay","year":"2025","unstructured":"Tremblay D, Ko A, Chrysafi P, How CJ, Zon R, Damon Houghton D et al (2025) Cytoreductive therapy reduces recurrent thrombosis in patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis: A global abdominal\/splanchnic thrombosis retrospective observational study (GASTRO-MPN) study of 757 patients. Blood 146(Supplement 1):1026","journal-title":"Blood"},{"issue":"2","key":"6970_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41375-020-0849-2","volume":"35","author":"A Alvarez-Larr\u00e1n","year":"2021","unstructured":"Alvarez-Larr\u00e1n A, D\u00edaz-Gonz\u00e1lez A, Such E, Mora E, Andrade-Campos M, Garc\u00eda-Hern\u00e1ndez C et al (2021) Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia 35(2):623\u2013627","journal-title":"Leukemia"},{"issue":"1\u20132","key":"6970_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/10428199909145710","volume":"35","author":"F Ravandi-Kashani","year":"1999","unstructured":"Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O\u2019Brien S, Markowitz A et al (1999) Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35(1\u20132):109\u2013118","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"6970_CR37","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3889\/oamjms.2018.320","volume":"6","author":"V Simeonovski","year":"2018","unstructured":"Simeonovski V, Breshkovska H, Duma S, Dohcheva-Karajovanov I, Damevska K, Nikolovska S (2018) Hydroxyurea Associated Cutaneous Lesions: A Case Report. Open Access Maced J Med Sci 6(8):1458\u20131461","journal-title":"Open Access Maced J Med Sci"},{"issue":"8","key":"6970_CR38","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","volume":"33","author":"T Barbui","year":"2019","unstructured":"Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N et al (2019) Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia 33(8):1996\u20132005","journal-title":"Leukemia"},{"issue":"5","key":"6970_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V et al (2012) Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN. Am J Hematol 87(5):552\u2013554","journal-title":"Am J Hematol"},{"issue":"1","key":"6970_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33\u201345","journal-title":"N Engl J Med"},{"issue":"1","key":"6970_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","volume":"152","author":"JC Hern\u00e1ndez-Boluda","year":"2011","unstructured":"Hern\u00e1ndez-Boluda JC, Alvarez-Larr\u00e1n A, G\u00f3mez M, Angona A, Amat P, Bellosillo B et al (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152(1):81\u201388","journal-title":"Br J Haematol"},{"issue":"3","key":"6970_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S et al (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: Findings from the MPN Landmark survey. Cancer 123(3):449\u2013458","journal-title":"Cancer"},{"issue":"7","key":"6970_CR43","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/S2352-3026(22)00139-9","volume":"9","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, Mascarenhas J (2022) Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance. Lancet Haematol 9(7):e462\u2013e3","journal-title":"Lancet Haematol"},{"issue":"19","key":"6970_CR44","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O\u2019Sullivan J et al (2023) Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol 41(19):3534\u20133544","journal-title":"J Clin Oncol"},{"issue":"1","key":"6970_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88\u201399","journal-title":"Lancet Oncol"},{"issue":"7","key":"6970_CR46","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","volume":"9","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P et al (2022) Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol 9(7):e480\u2013e92","journal-title":"Lancet Haematol"},{"issue":"17","key":"6970_CR47","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJMc1502524","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(17):1670\u20131671","journal-title":"N Engl J Med"},{"issue":"7","key":"6970_CR48","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","volume":"96","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A et al (2017) Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol 96(7):1113\u20131120","journal-title":"Ann Hematol"},{"issue":"8","key":"6970_CR49","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/ajh.27400","volume":"99","author":"P Guglielmelli","year":"2024","unstructured":"Guglielmelli P, Mora B, Gesullo F, Mannelli F, Loscocco GG, Signori L et al (2024) Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol 99(8):1550\u20131559","journal-title":"Am J Hematol"},{"key":"6970_CR50","doi-asserted-by":"publisher","first-page":"204062072513421","DOI":"10.1177\/20406207251342199","volume":"16","author":"S Koschmieder","year":"2025","unstructured":"Koschmieder S, Schulte C, von der Heyde E, Busque L, Boyer-Perrard F, Devos T et al (2025) Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study. Ther Adv Hematol 16:20406207251342199","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"6970_CR51","doi-asserted-by":"publisher","first-page":"e70000","DOI":"10.1002\/jha2.70000","volume":"6","author":"R Dunn","year":"2025","unstructured":"Dunn R, Long E, Gagnon LL, Harrison C, Yang Y, O\u2019Sullivan J (2025) Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety. EJHaem 6(1):e70000","journal-title":"EJHaem"},{"issue":"20","key":"6970_CR52","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","volume":"8","author":"AL S\u00f8rensen","year":"2024","unstructured":"S\u00f8rensen AL, Skov V, Kj\u00e6r L, Bj\u00f8rn ME, Eickhardt-Dalb\u00f8ge CS, Larsen MK et al (2024) Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. Blood Adv 8(20):5416\u20135425","journal-title":"Blood Adv"},{"issue":"7","key":"6970_CR53","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00277-024-05809-6","volume":"103","author":"F Palandri","year":"2024","unstructured":"Palandri F, Branzanti F, Venturi M, Dedola A, Fontana G, Loffredo M et al (2024) Real-life use of ropeg-interferon \u03b12b in polycythemia vera: patient selection and clinical outcomes. Ann Hematol 103(7):2347\u20132354","journal-title":"Ann Hematol"},{"issue":"15","key":"6970_CR54","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA et al (2015) Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126(15):1762\u20131769","journal-title":"Blood"},{"issue":"3","key":"6970_CR55","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196\u2013e208","journal-title":"Lancet Haematol"},{"issue":"4","key":"6970_CR56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3324\/haematol.2023.283958","volume":"110","author":"F Pasquier","year":"2025","unstructured":"Pasquier F, Pegliasco J, Martin JE, Marti S, Plo I (2025) New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-\u03b1 alter the natural history of the disease? Haematologica 110(4):850\u2013862","journal-title":"Haematologica"},{"issue":"5","key":"6970_CR57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clinthera.2024.03.005","volume":"46","author":"A Qin","year":"2024","unstructured":"Qin A (2024) Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment. Clin Ther 46(5):439\u2013440","journal-title":"Clin Ther"},{"issue":"6","key":"6970_CR58","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108(6):2037\u20132040","journal-title":"Blood"},{"issue":"5","key":"6970_CR59","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al (2022) Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36(5):1408\u20131411","journal-title":"Leukemia"},{"issue":"5","key":"6970_CR60","doi-asserted-by":"publisher","first-page":"e70137","DOI":"10.1002\/hem3.70137","volume":"9","author":"JJ Kiladjian","year":"2025","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al (2025) Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV). Hemasphere 9(5):e70137","journal-title":"Hemasphere"},{"issue":"3","key":"6970_CR61","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A et al (2021) Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol 8(3):e175\u2013e84","journal-title":"Lancet Haematol"},{"issue":"6","key":"6970_CR62","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/bjh.19813","volume":"205","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG et al (2024) Neutrophil\/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy. Br J Haematol 205(6):2287\u20132294","journal-title":"Br J Haematol"},{"issue":"1","key":"6970_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A, Wu D, Shao Z, Bai J et al (2023) A new dosing regimen of ropeginterferon alfa\u20132b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol 12(1):55","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"6970_CR64","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/bloodadvances.2025017938","volume":"10","author":"S Suo","year":"2026","unstructured":"Suo S, Fu R, Qin A, Shao Z, Bai J, Zhou H et al (2026) Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera. Blood Adv 10(2):507\u2013510","journal-title":"Blood Adv"},{"key":"6970_CR65","doi-asserted-by":"crossref","unstructured":"Lee JY, Yoon SS, Yang DH, Sohn SK, Yoon SY, Bang SM et al (2025) Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera. Cancer Res Treat [E-pub]","DOI":"10.4143\/crt.2025.552"},{"issue":"1","key":"6970_CR66","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00277-025-06185-5","volume":"104","author":"A Yacoub","year":"2025","unstructured":"Yacoub A, Abu-Zeinah G, Qin A, Tashi T, Da\u2019na W, Shih WJ et al (2025) PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera. Ann Hematol 104(1):335\u2013345","journal-title":"Ann Hematol"},{"issue":"6","key":"6970_CR67","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1159\/000544818","volume":"148","author":"J Mascarenhas","year":"2025","unstructured":"Mascarenhas J, Bose P, Hillis C, Yacoub A, Chaer FE, Maze D et al (2025) ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. Acta Haematol 148(6):675\u2013681","journal-title":"Acta Haematol"},{"key":"6970_CR68","doi-asserted-by":"publisher","first-page":"204062072513389","DOI":"10.1177\/20406207251338942","volume":"16","author":"A R\u00fcfer","year":"2025","unstructured":"R\u00fcfer A, Brand C, de Gottardi A, Fischli S, Melzer R, Odermatt U et al (2025) Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa-case report, review of the literature and multidisciplinary clinical practice recommendations. Ther Adv Hematol 16:20406207251338942","journal-title":"Ther Adv Hematol"},{"issue":"18","key":"6970_CR69","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Mesa RA, Hoffman R (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18):4706\u20134715","journal-title":"Blood"},{"issue":"12","key":"6970_CR70","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","volume":"93","author":"A Alvarez-Larr\u00e1n","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Mart\u00ednez-Avil\u00e9s L, Hern\u00e1ndez-Boluda JC, Ferrer-Mar\u00edn F, Antelo ML, Burgaleta C et al (2014) Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 93(12):2037\u20132043","journal-title":"Ann Hematol"},{"issue":"6","key":"6970_CR71","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41408-018-0091-6","volume":"8","author":"R Renso","year":"2018","unstructured":"Renso R, Aroldi A, Pioltelli P, Gambacorti-Passerini C, Elli EM (2018) Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. Blood Cancer J 8(6):56","journal-title":"Blood Cancer J"},{"issue":"5","key":"6970_CR72","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1038\/bcj.2016.34","volume":"6","author":"K Begna","year":"2016","unstructured":"Begna K, Abdelatif A, Schwager S, Hanson C, Pardanani A, Tefferi A (2016) Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. Blood Cancer J 6(5):e427","journal-title":"Blood Cancer J"},{"issue":"2","key":"6970_CR73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/jpm.2024.0221","volume":"28","author":"J Brennan-Cook","year":"2025","unstructured":"Brennan-Cook J, Rein L, Kuykendall A, Johnson N, Koch A, Taylor AO et al (2025) Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Myeloproliferative Neoplasms. J Palliat Med 28(2):257\u2013264","journal-title":"J Palliat Med"},{"issue":"6","key":"6970_CR74","first-page":"351","volume":"29","author":"BC Choi","year":"2006","unstructured":"Choi BC, Pak AW (2006) Multidisciplinarity, interdisciplinarity and transdisciplinarity in health research, services, education and policy: 1. Definitions, objectives, and evidence of effectiveness. Clin Invest Med 29(6):351\u2013364","journal-title":"Clin Invest Med"},{"issue":"2","key":"6970_CR75","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","volume":"36","author":"G Abu-Zeinah","year":"2022","unstructured":"Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM (2022) Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia 36(2):569\u2013572","journal-title":"Leukemia"},{"issue":"33","key":"6970_CR76","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098\u20134103","journal-title":"J Clin Oncol"},{"issue":"4","key":"6970_CR77","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Faculty BV (2022) Baveno VII - Renewing consensus in portal hypertension. J Hepatol 76(4):959\u2013974","journal-title":"J Hepatol"},{"issue":"3","key":"6970_CR78","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pon.3430","volume":"23","author":"KA Donovan","year":"2014","unstructured":"Donovan KA, Grassi L, McGinty HL, Jacobsen PB (2014) Validation of the distress thermometer worldwide: state of the science. Psychooncology 23(3):241\u2013250","journal-title":"Psychooncology"},{"issue":"9","key":"6970_CR79","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1182\/bloodadvances.2024015410","volume":"9","author":"J Liu","year":"2025","unstructured":"Liu J, Chin-Yee B, Ho J, Lazo-Langner A, Chin-Yee IH, Iansavitchene A et al (2025) Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review. Blood Adv 9(9):2108\u20132118","journal-title":"Blood Adv"},{"issue":"2","key":"6970_CR80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtha.2024.10.012","volume":"23","author":"KJ Barnum","year":"2025","unstructured":"Barnum KJ, Patell R, Berry J, Bauer KA (2025) Splanchnic vein thrombosis: management for the thrombosis specialist. J Thromb Haemost 23(2):404\u2013416","journal-title":"J Thromb Haemost"},{"issue":"25","key":"6970_CR81","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921\u20134928","journal-title":"Blood"},{"issue":"5","key":"6970_CR82","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ajh.26896","volume":"98","author":"JJ Kiladjian","year":"2023","unstructured":"Kiladjian JJ, Cassinat B (2023) Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. Am J Hematol 98(5):794\u2013800","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"6970_CR83","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12072-017-9810-5","volume":"12","author":"DC Valla","year":"2018","unstructured":"Valla DC (2018) Budd-Chiari syndrome\/hepatic venous outflow tract obstruction. Hepatol Int 12(Suppl 1):168\u2013180","journal-title":"Hepatol Int"},{"issue":"1","key":"6970_CR84","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver (2016) EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 64(1):179\u2013202","journal-title":"J Hepatol"},{"issue":"2","key":"6970_CR85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/bjh.15647","volume":"184","author":"MFF McMullin","year":"2018","unstructured":"McMullin MFF, Mead AJ, Ali S, Cargo C, Chen F, Ewing J et al (2018) A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. Br J Haematol 184(2):161\u2013175","journal-title":"Br J Haematol"},{"issue":"5","key":"6970_CR86","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/jcm13051412","volume":"13","author":"S Shalaby","year":"2024","unstructured":"Shalaby S, Miraglia R, Senzolo M (2024) Transjugular Intrahepatic Portosystemic Shunt in Nonmalignant Noncirrhotic Portal Vein Thrombosis and Portosinusoidal Vascular Disorder. J Clin Med 13(5):1412","journal-title":"J Clin Med"},{"issue":"8","key":"6970_CR87","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/ajh.27717","volume":"100","author":"MS Rana","year":"2025","unstructured":"Rana MS, Iftikhar M, Jadoon Y, Abdelmagid M, Viswanatha DS, He R et al (2025) The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates. Am J Hematol 100(8):1343\u20131353","journal-title":"Am J Hematol"},{"key":"6970_CR88","doi-asserted-by":"crossref","unstructured":"Regimbeau M, Mary R, Hermetet F, Girodon F (2022) Genetic Background of Polycythemia Vera. Genes (Basel) 13(4):637","DOI":"10.3390\/genes13040637"},{"issue":"5","key":"6970_CR89","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459\u2013468","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"6970_CR90","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2025-1021","volume":"146","author":"K Manz","year":"2025","unstructured":"Manz K, Schnoeder T, Palandri F, Branzanti F, Pahl H, Griesshammer M et al (2025) MPN with multiple driver clones show distinct patterns of therapy response and progression - MPN double driver. Blood 146(Supplement 1):1021","journal-title":"Blood"},{"issue":"3","key":"6970_CR91","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00277-023-05610-x","volume":"103","author":"M Garrote","year":"2024","unstructured":"Garrote M, L\u00f3pez-Guerra M, Garc\u00eda-Pag\u00e1n JC, Arellano-Rodrigo E, Ferrer-Mar\u00edn F, Hern\u00e1ndez-Boluda JC et al (2024) Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology. Ann Hematol 103(3):737\u2013747","journal-title":"Ann Hematol"},{"issue":"6","key":"6970_CR92","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00277-023-05217-2","volume":"102","author":"D Cattaneo","year":"2023","unstructured":"Cattaneo D, Bucelli C, Marchetti A, Lionetti M, Fermo E, Bellani V et al (2023) Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort. Ann Hematol 102(6):1409\u20131420","journal-title":"Ann Hematol"},{"issue":"8","key":"6970_CR93","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/s41375-025-02660-0","volume":"39","author":"O Mansier","year":"2025","unstructured":"Mansier O, Lippert E, Benajiba L, Ranta D, Girodon F, Ianotto JC et al (2025) A molecular signature predicts hematologic evolution in polycythemia vera patients. Leukemia 39(8):1937\u20131947","journal-title":"Leukemia"},{"issue":"1","key":"6970_CR94","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2020.06.045","volume":"74","author":"M Magaz","year":"2021","unstructured":"Magaz M, Alvarez-Larr\u00e1n A, Colomer D, L\u00f3pez-Guerra M, Garc\u00eda-Criado M, Mezzano G et al (2021) Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. J Hepatol 74(1):89\u201395","journal-title":"J Hepatol"},{"issue":"1","key":"6970_CR95","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jhep.2020.07.043","volume":"74","author":"JJ Kiladjian","year":"2021","unstructured":"Kiladjian JJ, Debureaux PE, Plessier A, Soret-Dulphy J, Valla D, Cassinat B et al (2021) Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. J Hepatol 74(1):251\u2013252","journal-title":"J Hepatol"},{"issue":"5","key":"6970_CR96","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","volume":"39","author":"U Gianelli","year":"2015","unstructured":"Gianelli U, Iurlo A, Cattaneo D, Bossi A, Cortinovis I, Augello C et al (2015) Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk Res 39(5):525\u2013529","journal-title":"Leuk Res"},{"issue":"6","key":"6970_CR97","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.12990","volume":"166","author":"A Alvarez-Larr\u00e1n","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Ancochea A, Garc\u00eda M, Climent F, Garc\u00eda-Pallarols F, Angona A et al (2014) WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol 166(6):911\u2013919","journal-title":"Br J Haematol"},{"issue":"2","key":"6970_CR98","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bjh.19938","volume":"206","author":"R Wang","year":"2025","unstructured":"Wang R, Shi Z, Zhang Y, Wei L, Duan M, Xiao M et al (2025) Development and validation of a deep learning model for morphological assessment of myeloproliferative neoplasms using clinical data and digital pathology. Br J Haematol 206(2):596\u2013606","journal-title":"Br J Haematol"},{"issue":"1","key":"6970_CR99","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1182\/hematology.2023000481","volume":"2023","author":"N Riva","year":"2023","unstructured":"Riva N, Ageno W (2023) How to manage splanchnic vein thrombosis in patients with liver disease. Hematol Am Soc Hematol Educ Program 2023(1):281\u2013288","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"6970_CR100","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1038\/bcj.2016.103","volume":"6","author":"V De Stefano","year":"2016","unstructured":"De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larr\u00e1n A, Iurlo A et al (2016) Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J 6(11):e493","journal-title":"Blood Cancer J"},{"issue":"4","key":"6970_CR101","first-page":"655","volume":"4","author":"L Naymagon","year":"2020","unstructured":"Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, Schiano T et al (2020) The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. BloodAdv 4(4):655\u2013666","journal-title":"BloodAdv"},{"issue":"3","key":"6970_CR102","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/bjh.16485","volume":"189","author":"N Curto-Garcia","year":"2020","unstructured":"Curto-Garcia N, Doyle AJ, Breen KA, McLornan DP, Radia DH, Hunt BJ et al (2020) Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. Br J Haematol 189(3):e79\u2013e81","journal-title":"Br J Haematol"},{"issue":"1","key":"6970_CR103","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ejh.13335","volume":"104","author":"D Tremblay","year":"2020","unstructured":"Tremblay D, Vogel AS, Moshier E, Hoffman R, Kremyanskaya M, Zhou S et al (2020) Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience. Eur J Haematol 104(1):72\u201373","journal-title":"Eur J Haematol"},{"issue":"10","key":"6970_CR104","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","volume":"35","author":"T Barbui","year":"2021","unstructured":"Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B et al (2021) Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia 35(10):2989\u20132993","journal-title":"Leukemia"},{"issue":"16","key":"6970_CR105","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1182\/blood.2024025627","volume":"145","author":"A Guy","year":"2025","unstructured":"Guy A, Morange PE, James C (2025) How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms. Blood 145(16):1769\u20131779","journal-title":"Blood"},{"issue":"9","key":"6970_CR106","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1038\/s41375-018-0199-5","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C et al (2018) Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia 32(9):2077\u20132081","journal-title":"Leukemia"},{"issue":"Suppl 4","key":"6970_CR107","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/ajh.27665","volume":"100","author":"N Szuber","year":"2025","unstructured":"Szuber N, Guglielmelli P, Gangat N (2025) Topics of Interest in Women With Myeloproliferative Neoplasms. Am J Hematol 100(Suppl 4):74\u201387","journal-title":"Am J Hematol"},{"issue":"2","key":"6970_CR108","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajh.24614","volume":"92","author":"L Pieri","year":"2017","unstructured":"Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M et al (2017) Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol 92(2):187\u2013195","journal-title":"Am J Hematol"},{"issue":"12","key":"6970_CR109","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1038\/s41375-019-0524-7","volume":"33","author":"J Mascarenhas","year":"2019","unstructured":"Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR et al (2019) A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia 33(12):2974\u20132978","journal-title":"Leukemia"},{"issue":"7","key":"6970_CR110","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","volume":"8","author":"G Finazzi","year":"2018","unstructured":"Finazzi G, De Stefano V, Barbui T (2018) Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer J 8(7):64","journal-title":"Blood Cancer J"},{"issue":"10","key":"6970_CR111","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1159\/000509376","volume":"43","author":"S Mancuso","year":"2020","unstructured":"Mancuso S, Santoro M, Accurso V, Agliastro G, Raso S, Di Piazza F et al (2020) Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors? Oncol Res Treat 43(10):526\u2013530","journal-title":"Oncol Res Treat"},{"issue":"34","key":"6970_CR112","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337","journal-title":"Eur Heart J"},{"issue":"2","key":"6970_CR113","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J et al (2019) A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol 184(2):176\u2013191","journal-title":"Br J Haematol"},{"issue":"5","key":"6970_CR114","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00277-021-04431-0","volume":"100","author":"I Kre\u010dak","year":"2021","unstructured":"Kre\u010dak I, Holik H, Coha B, Peri\u0107 MM, Zekanovi\u0107 I, Kre\u010dak MV et al (2021) Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera. Ann Hematol 100(5):1335\u20131336","journal-title":"Ann Hematol"},{"issue":"1","key":"6970_CR115","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjh.17130","volume":"193","author":"AL S\u00f8rensen","year":"2021","unstructured":"S\u00f8rensen AL, Knudsen TA, Skov V, Kjaer L, Holm N, Ellervik C et al (2021) Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: A retrospective cohort study. Br J Haematol 193(1):83\u201392","journal-title":"Br J Haematol"},{"issue":"8","key":"6970_CR116","first-page":"e16978","volume":"13","author":"DR Gavini","year":"2021","unstructured":"Gavini DR, Salvi DJ, Shah PH, Uma D, Lee JH, Hamid P (2021) Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review. Cureus 13(8):e16978","journal-title":"Cureus"},{"issue":"4","key":"6970_CR117","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/jha2.551","volume":"3","author":"A Mathur","year":"2022","unstructured":"Mathur A, Edman J, Liang L, Scott NW, Watson HG (2022) Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide. EJHaem 3(4):1305\u20131309","journal-title":"EJHaem"},{"issue":"2","key":"6970_CR118","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","volume":"86","author":"JQ Lin","year":"2022","unstructured":"Lin JQ, Li SQ, Li S, Kiamanesh EF, Aasi SZ, Kwong BY et al (2022) A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol 86(2):339\u2013344","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"6970_CR119","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1524-4733.2008.00400.x","volume":"12","author":"S Kripalani","year":"2009","unstructured":"Kripalani S, Risser J, Gatti ME, Jacobson TA (2009) Development and evaluation of the adherence to refills and medications scale (ARMS) among low-literacy patients with chronic disease. Value Health 12(1):118\u2013123","journal-title":"Value Health"},{"issue":"6","key":"6970_CR120","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00277-024-05704-0","volume":"103","author":"F Palandri","year":"2024","unstructured":"Palandri F, Auteri G, Abruzzese E, Caocci G, Bonifacio M, Mendicino F et al (2024) Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the RAMP Italian multicenter prospective study. Ann Hematol 103(6):1931\u20131940","journal-title":"Ann Hematol"},{"issue":"5","key":"6970_CR121","doi-asserted-by":"publisher","first-page":"e12566","DOI":"10.1111\/ijn.12566","volume":"23","author":"F G\u00f6kdo\u011fan","year":"2017","unstructured":"G\u00f6kdo\u011fan F, Kes D (2017) Validity and reliability of the Turkish Adherence to Refills and Medications Scale. Int J Nurs Pract 23(5):e12566","journal-title":"Int J Nurs Pract"},{"key":"6970_CR122","doi-asserted-by":"publisher","first-page":"e2300593","DOI":"10.1200\/PO.23.00593","volume":"8","author":"AT Kuykendall","year":"2024","unstructured":"Kuykendall AT, Ball S, Mora B, Mo Q, Al Ali N, Maffioli M et al (2024) Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. JCO Precis Oncol 8:e2300593","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"6970_CR123","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","volume":"15","author":"RA Mesa","year":"2015","unstructured":"Mesa RA, Verstovsek S, Gupta V, O Mascarenhas J, Atallah E, Burn T et al (2015) Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk 15(4):214\u2013221e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"6970_CR124","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.17192","volume":"193","author":"N Polverelli","year":"2021","unstructured":"Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M et al (2021) Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol 193(2):356\u2013368","journal-title":"Br J Haematol"},{"issue":"2","key":"6970_CR125","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.2023022345","volume":"143","author":"A Rampotas","year":"2024","unstructured":"Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C et al (2024) Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood 143(2):178\u2013182","journal-title":"Blood"},{"issue":"1","key":"6970_CR126","doi-asserted-by":"publisher","first-page":"e35661","DOI":"10.1002\/cncr.35661","volume":"131","author":"L Masarova","year":"2025","unstructured":"Masarova L, Mascarenhas J, Rampal R, Hu W, Livingston RA, Pemmaraju N (2025) Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer 131(1):e35661","journal-title":"Cancer"},{"issue":"2","key":"6970_CR127","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM et al (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118(2):401\u2013408","journal-title":"Blood"},{"issue":"4","key":"6970_CR128","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9(4):e301\u2013e11","journal-title":"Lancet Haematol"},{"issue":"2","key":"6970_CR129","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","volume":"38","author":"H Pasquer","year":"2024","unstructured":"Pasquer H, Daltro de Oliveira R, Vasseur L, Soret-Dulphy J, Maslah N, Zhao LP et al (2024) Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia 38(2):326\u2013339","journal-title":"Leukemia"},{"issue":"12","key":"6970_CR130","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F et al (2021) JAK2V617F variant allele frequency\u2009>\u200950% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J 11(12):199","journal-title":"Blood Cancer J"},{"key":"6970_CR131","doi-asserted-by":"publisher","first-page":"108123","DOI":"10.1016\/j.leukres.2025.108123","volume":"159","author":"L Tosoni","year":"2025","unstructured":"Tosoni L, Di Giusto S, Morelli G, Bergnach M, Callegari C, Stella R et al (2025) High JAK2V617F allele burden in low-risk PV: an additional recommendation to start early cytoreduction? Results from a multicentric study. Leuk Res 159:108123","journal-title":"Leuk Res"},{"issue":"1","key":"6970_CR132","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41408-024-01176-7","volume":"14","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, Ghirardi A, Fenili F, Finazzi MC, Castelli M et al (2024) Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis. Blood Cancer J 14(1):195","journal-title":"Blood Cancer J"},{"issue":"1","key":"6970_CR133","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41408-024-00994-z","volume":"14","author":"MK Larsen","year":"2024","unstructured":"Larsen MK, Skov V, Kj\u00e6r L, Eickhardt-Dalb\u00f8ge CS, Knudsen TA, Kristiansen MH et al (2024) Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study. Blood Cancer J 14(1):28","journal-title":"Blood Cancer J"},{"issue":"2","key":"6970_CR134","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG et al (2020) Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol 189(2):291\u2013302","journal-title":"Br J Haematol"},{"key":"6970_CR135","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S et al (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer 16:167","journal-title":"BMC Cancer"},{"issue":"10","key":"6970_CR136","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M et al (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 96(10):1653\u20131665","journal-title":"Ann Hematol"},{"key":"6970_CR137","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/CLEP.S162688","volume":"11","author":"N Brochmann","year":"2019","unstructured":"Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K et al (2019) Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clin Epidemiol 11:23\u201333","journal-title":"Clin Epidemiol"},{"issue":"4","key":"6970_CR138","doi-asserted-by":"publisher","first-page":"e6338","DOI":"10.1002\/pon.6338","volume":"33","author":"AAM Eppingbroek","year":"2024","unstructured":"Eppingbroek AAM, Lechner L, Bakker EC, Nijkamp MD, de Witte MA, Bolman CAW (2024) The personal impact of living with a myeloproliferative neoplasm. Psychooncology 33(4):e6338","journal-title":"Psychooncology"},{"key":"6970_CR139","doi-asserted-by":"publisher","first-page":"949003","DOI":"10.3389\/fendo.2022.949003","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K et al (2022) A systematic review and meta-analysis of endocrine-related adverse events associated with interferon. Front Endocrinol (Lausanne) 13:949003","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"6970_CR140","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood.2023020729","volume":"143","author":"S Robinson","year":"2024","unstructured":"Robinson S, Ragheb M, Harrison C (2024) How I treat myeloproliferative neoplasms in pregnancy. Blood 143(9):777\u2013785","journal-title":"Blood"},{"issue":"3","key":"6970_CR141","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ajh.26067","volume":"96","author":"N Gangat","year":"2021","unstructured":"Gangat N, Tefferi A (2021) Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol 96(3):354\u2013366","journal-title":"Am J Hematol"},{"issue":"11","key":"6970_CR142","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1097\/HS9.0000000000000793","volume":"6","author":"E Te Linde","year":"2022","unstructured":"Te Linde E, Boots LJE, Daenen LGM, de Witte MA, Bruns AHW (2022) High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis. Hemasphere 6(11):e793","journal-title":"Hemasphere"},{"issue":"11","key":"6970_CR143","first-page":"3496","volume":"109","author":"C Girmenia","year":"2024","unstructured":"Girmenia C, Ciceri F, Corradini P, Cuneo A, D\u2019Ancona F, Musto P et al (2024) Towards personalized prevention of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an ad hoc Italian expert panel. Haematologica 109(11):3496\u20133504","journal-title":"Haematologica"},{"issue":"4","key":"6970_CR144","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/10245332.2017.1385192","volume":"23","author":"T Devos","year":"2018","unstructured":"Devos T, Selleslag D, Zach\u00e9e P, Benghiat FS (2018) Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology 23(4):194\u2013200","journal-title":"Hematology"},{"issue":"4","key":"6970_CR145","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","volume":"33","author":"G De Maschmeyer","year":"2019","unstructured":"Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A et al (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia 33(4):844\u2009\u2013\u200986","journal-title":"Leukemia"},{"issue":"1","key":"6970_CR146","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/bjh.17096","volume":"193","author":"S Alimam","year":"2021","unstructured":"Alimam S, Jessica Ann Timms JA, Harrison CN, Dillon R, Mare T, DeLavallade H et al (2021) Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. Br J Haematol 193(1):150\u2013115","journal-title":"Br J Haematol"},{"key":"6970_CR147","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s41375-020-0877-y","volume":"34","author":"B Fattizzo","year":"2020","unstructured":"Fattizzo B, Giannotta JA, Scium\u00e8 M, Cattaneo D, Bucelli C, Fracchiolla NS et al (2020) Reply to COVID-19 in persons with haematological cancers: a focus on myeloid neoplasms and risk factors for mortality. Leukemia 34:1957\u20131960","journal-title":"Leukemia"},{"key":"6970_CR148","doi-asserted-by":"publisher","first-page":"1117815","DOI":"10.3389\/fonc.2023.1117815","volume":"13","author":"GA Palumbo","year":"2023","unstructured":"Palumbo GA, Cambria D, La Spina E, Duminuco A, Laneri A, Longo A et al (2023) Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. Front Oncol 13:1117815","journal-title":"Front Oncol"},{"issue":"8","key":"6970_CR149","doi-asserted-by":"publisher","first-page":"e7185","DOI":"10.1002\/cam4.7185","volume":"13","author":"CP Williams","year":"2024","unstructured":"Williams CP, Deng L, Caston NE, Gallagher K, Angove R, Pisu M et al (2024) Understanding the financial cost of cancer clinical trial participation. Cancer Med 13(8):e7185","journal-title":"Cancer Med"},{"issue":"1","key":"6970_CR150","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ejh.12887","volume":"99","author":"S Goel","year":"2017","unstructured":"Goel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T et al (2017) Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. Eur J Haematol 99(1):36\u201341","journal-title":"Eur J Haematol"},{"key":"6970_CR151","doi-asserted-by":"publisher","first-page":"1333230","DOI":"10.3389\/fmed.2024.1333230","volume":"11","author":"Y Xing","year":"2024","unstructured":"Xing Y, Wang X, Zhang C, Yuan W, Chen X, Luan W (2024) Characteristics and duties of clinical research nurses: a scoping review. Front Med (Lausanne) 11:1333230","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"6970_CR152","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1752-8062.2011.00365.x","volume":"4","author":"M Bevans","year":"2011","unstructured":"Bevans M, Hastings C, Wehrlen L, Cusack G, Matlock AM, Miller-Davis C et al (2011) Defining clinical research nursing practice: results of a role delineation study. Clin Transl Sci 4(6):421\u2013427","journal-title":"Clin Transl Sci"}],"updated-by":[{"DOI":"10.1007\/s00277-026-07207-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06970-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06970-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06970-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:01:52Z","timestamp":1784966512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06970-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":152,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6970"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06970-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-026-07207-6","URL":"https:\/\/doi.org\/10.1007\/s00277-026-07207-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FP reports honoraria and consulting fees from Novartis, GSK, BMS, Incyte, Sanofi, Takeda, Sobi, AOP. All other authors declare that they have no conflicts of interest related to this manuscript.","order":1,"name":"Ethics","label":"Declarations","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent for publication has been obtained from the patients. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The article is exempt from Ethical Committee approval since it is related only to two clinical cases.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"251"}}